According to Sunovion Pharmaceuticals, Zetonna ciclesonide nasal aerosol for the treatment of perennial and seasonal allergic rhinitis is now available throughout the US. The company announced in May that it would launch the product by this fall. Sunovion also markets Omnaris ciclesonide nasal spray for the treatment of allergic rhinitis and Alvesco ciclesonide … [Read more...] about Sunovion launches Zetonna nasal aerosol in US
Medical
Health Canada issues advisory on potential Pulmicort Turbuhaler device failure
Health Canada has issued an advisory to health care professionals that "AstraZeneca Canada has received a small number of product complaints for Pulmicort Turbuhaler, 200 µg per metered dose (200 doses) regarding the malfunction of the delivery device that results in a failure to dispense the dose of medication." According to the notice, the devices sometimes fail to … [Read more...] about Health Canada issues advisory on potential Pulmicort Turbuhaler device failure
All UK children to receive nasal flu vaccine free of charge — eventually
The UK Department of Health has announced that Health Secretary Andrew Lansley has agreed to a flu vaccination program recommended by a committee of independent experts that will provide MedImmune's Fluenz intranasal vaccine to all children aged 2 to 17 at no cost. Fluenz is known as FluMist in the US. Asthmatic children and those with other risk factors were already … [Read more...] about All UK children to receive nasal flu vaccine free of charge — eventually
UK supermarket chain to begin selling inhalers over the counter
Supermarket chain Asda says that it will become the first retailer in the UK to sell asthma reliever inhalers over the counter when its pharmacies begin offering salbutamol (albuterol) inhalers for sale on July 24. Asda has pharmacies in 218 stores. Patients over the age of 16 will be able to purchase two inhalers for £7 after filling out a simple questionnaire. … [Read more...] about UK supermarket chain to begin selling inhalers over the counter
Safety study of inhaled alpha1-proteinase inhibitor for CF to begin this year
Grifols has announced that its inhaled alpha1-proteinase inhibitor received orphan drug designation from the FDA in April 2012 and that the company will begin a safety study of the drug by the end of the year. Grifols markets intravenous alpha1-proteinase inhibitor, derived from human plasma, as Prolastin-C as a treatment for alpha1-antitrypsin (AAT) deficiency and is … [Read more...] about Safety study of inhaled alpha1-proteinase inhibitor for CF to begin this year
Results from four Phase 3 studies of GSK’s LAMA/LABA inhaler for COPD
GlaxoSmithKline and Theravance have announced results from four Phase 3 studies of its umeclidinium bromide (UMEC)/vilanterol (VI) combination DPI for the treatment of COPD. The studies include two 24-week efficacy studies and two 24-week active comparator studies comparing UMEC/VI with tiotropium. UMEC is a a long-acting muscarinic antagonist (LAMA) and vilanterol is … [Read more...] about Results from four Phase 3 studies of GSK’s LAMA/LABA inhaler for COPD
Regency launches study of Sprix ketorolac nasal spray
Regency Therapeutics has announced the initiation of the 18-month AMPED (Acute Management of Pain from the Emergency Department) registry study to compare patient response to Sprix ketorolac tromethamine nasal spray used to treat pain in emergency departments to outcomes for patients prescribe oral narcotics. The study will be conducted in 15 hospitals, including the … [Read more...] about Regency launches study of Sprix ketorolac nasal spray
Civitas initiates Phase 2a study of inhaled L-dopa
Civitas Therapeutics has announced the initiation of a Phase 2a clinical trial of its CVT-301 inhaled L-dopa for the treatment of motor fluctuations in patients with Parkinson’s disease. CVT-301 is formulated and delivered using the company's proprietary Arcus dry powder technology. Development of the product is being funded in part by the Michael J. Fox Foundation … [Read more...] about Civitas initiates Phase 2a study of inhaled L-dopa
Savara announces Phase I study results for AeroVanc, funding for Phase 2
Savara Pharmaceuticals has announced positive top-line results from a Phase 1 study of its AeroVanc inhaled dry powder formulation of vancomycin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in patients with cystic fibrosis. According to the company, the study demonstrated that AeroVanc was well tolerated, that clearance of the … [Read more...] about Savara announces Phase I study results for AeroVanc, funding for Phase 2
Alnylam inhaled RSV drug misses primary endpoint in Phase 2b study
Alnylam Pharmaceuticals says that its ALN-RSV01 inhaled RNAi drug failed to meet the primary endpoint of a Phase 2b study, not significantly reducing the incidence of bronchiolitis obliterans syndrome (BOS) at 180 days after infection in lung transplant patients infected with respiratory syncytial virus (RSV) in an “intent-to-treat” (ITTc) analysis, but that it met … [Read more...] about Alnylam inhaled RSV drug misses primary endpoint in Phase 2b study